Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/04/2014US8664180 Ophthalmic compositions containing diglycine
03/04/2014US8664177 Peptide compositions and methods for treating patients
03/04/2014US8663961 Inhibitors of Bruton's tyrosine kinase
03/04/2014US8663704 Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
03/04/2014US8663703 Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them
03/04/2014US8663700 Drug loaded polymeric nanoparticles and methods of making and using same
03/04/2014US8663699 Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
03/04/2014US8663696 Film delivery system for tetrahydrolipstatin
03/04/2014US8663695 Formulations and methods for treating rhinosinusitis
03/04/2014US8663693 Nanoparticulate formulations of fenofibrate
03/04/2014US8663685 Sustained release aminopyridine composition
03/04/2014US8663684 Lactose and cellulose-based tableting aid
03/04/2014US8663683 Sustained-release formulations of topiramate
03/04/2014US8663681 Oral dosage forms comprising progesterone and methods of making and using the same
03/04/2014US8663680 Transparent transdermal nicotine delivery devices
03/04/2014US8663679 Compositions for improving breast health in women
03/04/2014US8663678 Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
03/04/2014US8663677 Controlled release system and manufacturing method thereof
03/04/2014US8663668 Preservative for medical devices
03/04/2014US8663663 Topical compositions to treat circulatory disorders
03/04/2014US8663662 Stable pharmaceutical composition and methods of using same
03/04/2014US8663659 Orally administrable films
03/04/2014US8663658 Revaprazan-containing solid dispersion and process for the preparation thereof
03/04/2014US8663657 Nucleic acid constructs
03/04/2014US8663652 Regeneration of endogenous myocardial tissue
03/04/2014US8663651 T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
03/04/2014US8663639 Formulations for treating ocular diseases and conditions
03/04/2014US8663618 Surface modified porous polymers for enhanced cell growth
03/04/2014US8663617 Wound healing peptides and methods of use thereof
03/04/2014US8663609 Composition comprising a polyol, a sugar silicone surfactant and a oil-soluble polar modified polymer
03/04/2014US8663608 Hydroxytyrosol compounds
03/04/2014US8663606 Method of producing a cationic liposomal preparation comprising a lipophilic compound
03/04/2014CA2737463C Freeze-dried powder preparation of tetrodotoxin and the producing method thereof
03/04/2014CA2696335C Gel containing pirfenidone
03/04/2014CA2675374C Formulations for parenteral administration of amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
03/04/2014CA2565188C Compounds and compositions for delivering active agents
03/04/2014CA2278854C Use of the gastrointestinal lipase inhibitor tetrahydrolipstatin for treating type ii diabetes
02/2014
02/28/2014CA2819967A1 Pirfenidone therapy
02/27/2014WO2014032019A2 Compounds and methods of use thereof for treating tumors
02/27/2014WO2014031979A1 Reducing the reproductive capacity of mammals
02/27/2014WO2014031975A1 Anxiolytic composition, formulation and method of use
02/27/2014WO2014031964A1 Composition for the treatment of migraine headaches
02/27/2014WO2014031937A1 Novel 4,6-disubstituted aminopyrimidine derivatives
02/27/2014WO2014031936A2 Heterocyclic modulators of hif activity for treatment of disease
02/27/2014WO2014031933A2 Heterocyclic modulators of hif activity for treatment of disease
02/27/2014WO2014031928A2 Heterocyclic modulators of hif activity for treatment of disease
02/27/2014WO2014031901A1 Methods of use for monomethyl fumarate and prodrugs thereof
02/27/2014WO2014031897A1 Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
02/27/2014WO2014031894A1 Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
02/27/2014WO2014031892A1 Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
02/27/2014WO2014031875A1 Treatment of sickle cell disease and inflammatory conditions
02/27/2014WO2014031874A1 Phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering active agents
02/27/2014WO2014031873A2 Benzofurazan anti-amyloid compounds and methods
02/27/2014WO2014031856A1 Combination therapy using pi3 kinase and braf inhibitors
02/27/2014WO2014031844A1 Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
02/27/2014WO2014031837A1 Compositions and methods for enhancing sialic acid levels in tissue
02/27/2014WO2014031836A1 Managing weight loss and body mass
02/27/2014WO2014031815A1 Pyrazolopyrimidine compounds
02/27/2014WO2014031792A2 Methods of treating epilepsy or tatus epilepticus
02/27/2014WO2014031791A1 Process for preparing antiviral compounds
02/27/2014WO2014031784A1 Compounds for the treatment of paramoxyvirus viral infections
02/27/2014WO2014031769A2 Treatment of diseases associated with inflammation
02/27/2014WO2014031762A1 Benzocyclooctyne compounds and uses thereof
02/27/2014WO2014031759A2 Inhibitors of crl4 ubiquitin ligase and uses thereof
02/27/2014WO2014031755A1 Fendiline derivatives and methods of use thereof
02/27/2014WO2014031681A1 Inhibiting gram positive bacteria
02/27/2014WO2014031665A1 Antibodies to quetiapine haptens and use thereof
02/27/2014WO2014031649A1 Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
02/27/2014WO2014031601A1 Haptens of risperidone and paliperidone
02/27/2014WO2014031600A1 Haptens of quetiapine for use in immunoassays
02/27/2014WO2014031587A1 Haptens of olanzipine
02/27/2014WO2014031586A2 Methods for treating cardiovascular diseases
02/27/2014WO2014031584A1 Haptens of aripiprazole and their use in immunoassays
02/27/2014WO2014031517A1 Novel azabenzimidazole tetrahydrofuran derivatives
02/27/2014WO2014031515A1 Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
02/27/2014WO2014031504A1 Novel formulations and uses for curcuma extracts
02/27/2014WO2014031491A2 Extended production of nitric oxide from microencapsulated chemical reactants
02/27/2014WO2014031487A1 Bivalent inhibitors of iap proteins and therapeutic methods using the same
02/27/2014WO2014031468A1 Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
02/27/2014WO2014031465A1 Novel azabenzimidazole tetrahydropyran derivatives
02/27/2014WO2014031445A1 Novel benzimidazole tetrahydropyran derivatives
02/27/2014WO2014031441A1 Novel benzimidazole tetrahydrofuran derivatives
02/27/2014WO2014031438A2 SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
02/27/2014WO2014031403A1 Use of morphine analogs for animal health
02/27/2014WO2014031242A1 Retinoids and use thereof
02/27/2014WO2014031204A2 Carbohydrate-selective receptors
02/27/2014WO2014031177A1 Trans-clomiphene formulations and uses thereof
02/27/2014WO2014031167A1 Compounds and methods for treatment of hypertension
02/27/2014WO2014031165A1 Compounds and methods of treating diabetes
02/27/2014WO2014031161A1 Chemical compositions
02/27/2014WO2014031125A1 Pro-neurogenic compounds
02/27/2014WO2014031087A1 Natural synergistic formulations containing andrographis paniculata extracts for supporting the inhibition of cartilate degradation in degenerative joint disease
02/27/2014WO2014031034A1 Pharmaceutical compositions containing ipidacrine and use thereof to treat potency disorders and other sexual activity disorders
02/27/2014WO2014031026A1 Method for restoring male sex drive (libido) using a food supplement for restoring male sex drive (libido)
02/27/2014WO2014030975A1 Method for manufacturing carbon nanotube-based anti-cancer agent suppressing cancer cell resistance
02/27/2014WO2014030974A1 Carbon nanotube-based anti-cancer agent suppressing cancer cell resistance
02/27/2014WO2014030972A1 Anticancer composition
02/27/2014WO2014030763A1 Anti-tumor agent
02/27/2014WO2014030743A1 Heterocycic compound
02/27/2014WO2014030731A1 Method for producing polyphenol composition
1 ... 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 ... 7860